Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHAMP: NVK-002 in Children With Myopia
NCT03350620Phase 3Completed
- Sponsor
- Vyluma
- Start
- Nov 2017
- Primary completion
- Sep 2022
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 6
01
Overview
A Phase 3 trial of NVK002 in myopia, sponsored by Vyluma. Started Nov 2017; status: completed.
02
Drugs
NVK002
03
Conditions
myopia
Beyond the preview
Go deeper on NCT03350620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03350620.